| Similar Articles |
|---|
 |
Pharmaceutical Executive
February 1, 2013
Julian Upton |
Turkey: A Promise Restored? After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase.   |
Pharmaceutical Executive
May 1, 2012 |
Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory. |
Pharmaceutical Executive
December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Pharmaceutical Executive
August 1, 2012 |
Country Report: Mexico Jim O'Neill, chief economist at Goldman Sachs declared that by 2020 Mexico would be the seventh largest economy in the world, surpassing both India and Russia. The Mexican pharmaceutical industry has seen some significant changes over the last four years. |
Pharmaceutical Executive
February 1, 2013 |
Country Report: Australia In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally. |
Pharmaceutical Executive
October 1, 2006
Ray Hill |
China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge. |
Pharmaceutical Executive
August 1, 2011
Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. |
BusinessWeek
October 1, 2009
Stanley Reed |
Turkey's Shift to a More Open Economy Applying for EU membership has sped up reforms, and that has helped the country weather the current crisis. |
Pharmaceutical Executive
September 1, 2012
Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive
July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
October 1, 2011
William Looney |
The East is Up Candan Karabagli is CEO of Turkey's largest pharmaceutical company, Abdi Ibrahim, where she is responsible for consolidating the company's lead position in Turkey through more in-house R&D and licensing deals with innovative companies while building a stronger regional footprint. |
Pharmaceutical Executive
August 1, 2008 |
Harbingers of Change The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
BusinessWeek
June 16, 2011
Suzy Hansen |
Turkey's Moment Turkey is showing the world how a Muslim country in a turbulent region can achieve stability and prosperity. Will it last? |
Pharmaceutical Executive
February 1, 2011
Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
May 1, 2007 |
Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge. |
Chemistry World
January 3, 2013
Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
Pharmaceutical Executive
October 1, 2011 |
Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy. |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Pharmaceutical Executive
August 1, 2012 |
Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
Chemistry World
June 5, 2009
Anna Lewcock |
Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts. |
Pharmaceutical Executive
August 1, 2005
Lena Chow |
Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market. |
BusinessWeek
April 15, 2010
Bryant & Holland |
Turkey's Moment Its economy is hot again after a painful 2009, and some economists say it's a Germany in the making. The politics, though, are raucous. |
Pharmaceutical Executive
October 1, 2011
Daniel Vasella |
Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D. |
Pharmaceutical Executive
November 1, 2008 |
No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring? |
Inc.
April 2007
Stephanie Clifford |
Fully Committed Bulent Celebi has set up an American-style company in Turkey, where he enjoys advantages his competition can only dream of. |
BusinessWeek
December 2, 2010
Norman Pearlstine |
Norman Pearlstine Talks with Mehmet Sinsek An interview with Turkey's Finance Minister on why its economy is growing so fast. |
BusinessWeek
July 29, 2010
James G. Neuger |
Cameron Backs the Turks, Rattles the EU The British PM says it's time Turkey got into the European Union. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
The Motley Fool
December 27, 2007
Brian Orelli |
Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there. |
Pharmaceutical Executive
March 1, 2013 |
China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China. |
The Motley Fool
July 25, 2011
Eric Dutram |
What's Crushing the Turkey ETF? Many analysts are growing increasingly worried over the health of the Turkish economy. |
IndustryWeek
June 1, 2008
Adrienne Selko |
Global Hot Spots 2008: Revealing Global Manufacturing's Best Kept Secrets When expanding your supply chains overseas, it's vital that you do your homework to understand a country's cultural and business practices. |
The Motley Fool
October 19, 2005
David Compton |
Istanbul Beckons To whet your appetite in Turkish stocks, try investing in Turkey's largest mobile-phone operator and the country's only American Depositary Receipt (ADR) to be listed on the New York Stock Exchange -- Turkcell. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
BusinessWeek
October 11, 2004
John Rossant |
Turkey At The EU's Door Turkey's decades-long quest to join the European Union looks set to take a great leap forward. But while official pronouncements sound friendly, popular opposition is rising. |
Pharmaceutical Executive
October 1, 2005 |
Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies. |
The Motley Fool
September 25, 2008
Brian Lawler |
Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors. |
The Motley Fool
July 11, 2007
Brian Lawler |
Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note. |
Pharmaceutical Executive
October 1, 2011 |
Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public. |
BusinessWeek
February 9, 2004
John Rossant |
Turkey's EU Bid: Resistance Is On The Rise When it comes to its ally Turkey, the U.S. has long had a consistent goal: The European Union should take in the largely Muslim eastern Mediterranean nation as a full member. Back in Europe, though, that message isn't going over well. |
Pharmaceutical Executive
September 1, 2005
Wolfgang Klietmann |
Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact. |
| Knowledge@Wharton |
Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." |
Bio-IT World
January 21, 2005 |
How IT Can Decrease Time-to-Market in Clinical Trials Pharma manufacturers can learn from their industrial counterparts: Integrating systems can accelerate product delivery. |
BusinessWeek
May 27, 2010
Ben Holland |
Greece Can Learn IMF Austerity from Turkey A banking crisis in 2001 slammed the Turks, but they moved fast to carry out a tough IMF plan -- and have plenty to teach the Greeks |
